权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Integrating systems immunology with immunometabolism and cancer immunity

将系统免疫学与免疫代谢和癌症免疫相结合

基本信息

批准号：
10442703
负责人：
Hongbo Chi
金额：
$ 105.55万
依托单位：
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-01 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10442703
关键词：
Address Algorithms Area Biological Process CRISPR screen Cells Cellular Metabolic Process Dendritic Cells Development FRAP1 gene Foundations Goals Heterogeneity Homeostasis Immune Immune signaling Immunity Immunology Immunooncology Inflammation Link Malignant Childhood Neoplasm Malignant Neoplasms Metabolic Metabolic Control Metabolic Pathway Metabolism Nutrient Pathway interactions Positioning Attribute Principal Investigator Process Program Description Proteomics Research Signal Transduction System Systems Biology T-Lymphocyte T-Lymphocyte Subsets Testing Therapeutic Tissues Tumor Immunity Work adaptive immune response bench-to-bedside translation cancer immunotherapy cancer therapy clinical development clinical translation experience human disease immune function improved in vivo innovation insight interdisciplinary approach novel pre-clinical programs rapid growth refractory cancer stemness tumor microenvironment

项目摘要

Program Description/Abstract Metabolism is the core process underlying essentially all biological functions. The goal of our research program is to discover the mechanisms linking the metabolic state of immune cells with tissue homeostasis and antitumor immunity, and to use these insights for development of better cancer treatments. We approach these questions by integrating hypothesis-driven and systems immunology approaches, and our work has produced innovation in three main areas. First, we revealed the principle of metabolic reprogramming for T cell fate, state and tolerance. Our earlier findings in metabolic control of T cell fate and state, including T cell subset-specific requirement of Warburg metabolism and mTOR signaling, contributed to the foundation and rapid growth of the immunometabolism field. More recently, we identified metabolic heterogeneity in vivo that underlies T cell fate between stemness and terminal differentiation in tumor microenvironment and inflammation, and the cycle of metabolic quiescence and quiescence exit in immune development and function. Second, we defined mechanisms of nutrient and immune signaling. We identified how nutrient and autophagic signals serve as potent regulators of cellular metabolism, and how dendritic cell-derived immune and metabolic signals are integrated by T cells. Third, we combined the traditional hypothesis-driven or ‘reductionist’ approach with systems biology principles, including in-house development of network algorithm NetBID, pooled in vivo CRISPR screening and systems proteomics, which led to the identification of new concepts and ‘hidden drivers’ in immunometabolism that cannot be surmised from simpler systems. More importantly, these approaches enabled the discovery of novel immuno-oncology targets with a clear path to clinical translation into innovative therapeutics for pediatric cancers. Our systems immunology strategies provide functionally- relevant discovery platforms to support future research in metabolic control of immunity and cancer. Specifically, the future research program will address three fundamental questions in immunometabolism and antitumor immunity, by testing the central hypothesis that immunometabolic pathways are inextricably connected to the mechanisms of adaptive immune responses and antitumor immunity; by understanding these connections, we gain new targets for the treatment of cancer: 1) How are nutrient signals sensed and integrated by immune cells? 2) How can immunometabolism be rewired to improve antitumor immunity? 3) Can we break metabolic barriers to cancer immunity and therapy, especially in therapeutically-resistant cancers? We will focus on T cells, the cornerstone for cancer immunotherapy, to gain in-depth insights, but we anticipate the findings can be tested and extended into other immune cells. Our experience in the application of multidisciplinary approaches, combined with our new development and use of novel preclinical and human disease systems for cancer immunotherapy, makes us uniquely positioned to produce fundamental discoveries in immunometabolism and clinical translation for cancer treatments by reprogramming metabolic pathways.

程序描述/文摘